BRPI0906519A2 - Compostos de 3h--[1,2,3]triazolo[4,5-d]pirimidina, seu uso como mtor cinase e inibidores de pi3 cinase, e sua síntese - Google Patents

Compostos de 3h--[1,2,3]triazolo[4,5-d]pirimidina, seu uso como mtor cinase e inibidores de pi3 cinase, e sua síntese

Info

Publication number
BRPI0906519A2
BRPI0906519A2 BRPI0906519-9A BRPI0906519A BRPI0906519A2 BR PI0906519 A2 BRPI0906519 A2 BR PI0906519A2 BR PI0906519 A BRPI0906519 A BR PI0906519A BR PI0906519 A2 BRPI0906519 A2 BR PI0906519A2
Authority
BR
Brazil
Prior art keywords
kinase
triazolo
synthesis
pyrimidine compounds
kinase inhibitors
Prior art date
Application number
BRPI0906519-9A
Other languages
English (en)
Inventor
Christoph Martin Dehnhardt
Aranapakam Mudumbai Venkatesan
Efren Guillermo Delos Santos
Zecheng Chen
Osvaldo Dos Santos
Natasja Brooijmans
Arie Zask
Jeroen Cunera Verheijen
Semiranis Ayral-Kaloustian
Original Assignee
Wyeth Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wyeth Llc filed Critical Wyeth Llc
Publication of BRPI0906519A2 publication Critical patent/BRPI0906519A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Urology & Nephrology (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
BRPI0906519-9A 2008-01-15 2009-01-14 Compostos de 3h--[1,2,3]triazolo[4,5-d]pirimidina, seu uso como mtor cinase e inibidores de pi3 cinase, e sua síntese BRPI0906519A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US2108408P 2008-01-15 2008-01-15
US3468008P 2008-03-07 2008-03-07
PCT/US2009/030939 WO2009091788A1 (en) 2008-01-15 2009-01-14 3h-[1,2,3]triazolo[4,5-d]pyrimidine compounds, their use as mtor kinase and pi3 kinase inhibitors, and their syntheses

Publications (1)

Publication Number Publication Date
BRPI0906519A2 true BRPI0906519A2 (pt) 2015-07-14

Family

ID=40377318

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0906519-9A BRPI0906519A2 (pt) 2008-01-15 2009-01-14 Compostos de 3h--[1,2,3]triazolo[4,5-d]pirimidina, seu uso como mtor cinase e inibidores de pi3 cinase, e sua síntese

Country Status (21)

Country Link
US (1) US20090181963A1 (pt)
EP (1) EP2252296A1 (pt)
JP (1) JP2011510010A (pt)
KR (1) KR20100113567A (pt)
CN (1) CN102014914A (pt)
AP (1) AP2010005346A0 (pt)
AU (1) AU2009205501A1 (pt)
BR (1) BRPI0906519A2 (pt)
CA (1) CA2712267A1 (pt)
CO (1) CO6321259A2 (pt)
CR (1) CR11568A (pt)
DO (1) DOP2010000217A (pt)
EA (1) EA201001017A1 (pt)
EC (1) ECSP10010346A (pt)
IL (1) IL206820A0 (pt)
MA (1) MA32341B1 (pt)
MX (1) MX2010007746A (pt)
NI (1) NI201000119A (pt)
SV (1) SV2010003621A (pt)
WO (1) WO2009091788A1 (pt)
ZA (2) ZA201004603B (pt)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CL2008003798A1 (es) 2007-12-19 2009-10-09 Amgen Inc Compuestos derivados de heterobiciclos aromaticos sustituidos, inhibidores de pi3 quinasa; composicion farmaceutica; utiles en el tratamiento de cancer, melanomas, glioblastomas, entre otras enfermedades.
US20110053907A1 (en) * 2008-03-27 2011-03-03 Auckland Uniservices Limited Substituted pyrimidines and triazines and their use in cancer therapy
TWI378933B (en) 2008-10-14 2012-12-11 Daiichi Sankyo Co Ltd Morpholinopurine derivatives
US8461158B2 (en) * 2009-03-27 2013-06-11 Pathway Therapeutics Inc. Pyrimidinyl and 1,3,5-triazinyl benzimidazole sulfonamides and their use in cancer therapy
CA2766151A1 (en) * 2009-06-24 2010-12-29 Genentech, Inc. Oxo-heterocycle fused pyrimidine compounds, compositions and methods of use
US8486939B2 (en) * 2009-07-07 2013-07-16 Pathway Therapeutics Inc. Pyrimidinyl and 1,3,5-triazinyl benzimidazoles and their use in cancer therapy
PH12012501581A1 (en) 2010-02-03 2012-10-22 Signal Pharm Llc Identification of lkb1 mutation as a predictive biomarker for sensitivity to tor kinase inhibitors
EP3170813B1 (en) 2010-10-06 2018-12-12 GlaxoSmithKline LLC Benzimidazole derivatives as pi3 kinase inhibitors
CA2831582C (en) 2011-03-28 2019-01-08 Mei Pharma, Inc. (alpha-substituted aralkylamino and heteroarylalkylamino) pyrimidinyl and 1,3,5-triazinyl benzimidazoles, pharmaceutical compositions thereof, and their use in treating proliferative diseases
PE20141794A1 (es) * 2011-11-01 2014-12-17 Exelixis Inc N-(3-{[(3-{[2-cloro-5-(metoxi)fenil]amino}quinoxalin-2-il)amino]sulfonil}fenil)-2-metilalaninamida como inhibidor de fosfatidilinositol 3-quinasa para el tratamiento de neoplasias linfoproliferativas
US9499561B2 (en) 2012-04-10 2016-11-22 Shanghai Yingli Pharmaceutical Co., Ltd. Fused pyrimidine compound, and preparation method, intermediate, composition, and uses thereof
KR20160027219A (ko) 2012-05-23 2016-03-09 에프. 호프만-라 로슈 아게 내배엽 및 간세포를 수득하고 사용하는 조성물 및 방법
AU2013203714B2 (en) 2012-10-18 2015-12-03 Signal Pharmaceuticals, Llc Inhibition of phosphorylation of PRAS40, GSK3-beta or P70S6K1 as a marker for TOR kinase inhibitory activity
JP6382945B2 (ja) 2013-04-17 2018-08-29 シグナル ファーマシューティカルズ，エルエルシー ジヒドロピラジノ−ピラジンによる癌治療
EP2986321A1 (en) 2013-04-17 2016-02-24 Signal Pharmaceuticals, LLC Combination therapy comprising a tor kinase inhibitor and a cytidine analog for treating cancer
HK1221150A1 (zh) 2013-04-17 2017-05-26 西格诺药品有限公司 用二氢吡嗪并-吡嗪类对癌症的治疗
MX368286B (es) 2013-04-17 2019-09-27 Signal Pharm Llc Terapia de combinacion que comprende un inhibidor de tor cinasa y un compuesto de quinazolinona 5-sustituida para tratar cancer.
BR112015026257B1 (pt) 2013-04-17 2022-12-20 Signal Pharmaceuticals, Llc Uso de um composto dihidropirazino-pirazina e enzalutamida, composição farmacêutica que os compreende, e kit
CN105339008A (zh) 2013-04-17 2016-02-17 西格诺药品有限公司 用于治疗癌症的包括tor激酶抑制剂和n-(3-(5-氟-2-(4-(2-甲氧基乙氧基)苯基氨基)嘧啶-4-基氨基)苯基)丙烯酰胺的组合疗法
MX393164B (es) 2013-04-17 2025-03-21 Signal Pharm Llc Formulaciones farmacéuticas, proceso, formas sólidas y métodos de uso relacionados con 1-etil-7-(2-metil-6-(1h-1,2,4-triazol-3-ii)piridin-3-ii)-3,4-dihidropirazino[2,3-b]pirazin-2(1h)-ona.
NZ629486A (en) 2013-05-29 2017-11-24 Signal Pharm Llc Pharmaceutical compositions of 7-(6-(2-hydroxypropan-2-yl)pyridin-3-yl)-1-((trans)-4-methoxycyclohexyl)-3,4-dihydropyrazino [2,3-b]pyrazin-2(1h)-one, a solid form thereof and methods of their use
WO2015043398A1 (zh) * 2013-09-30 2015-04-02 上海璎黎药业有限公司 稠合嘧啶类化合物、中间体、其制备方法、组合物和应用
EP3131551A4 (en) 2014-04-16 2017-09-20 Signal Pharmaceuticals, LLC SOLID FORMS COMPRISING 1-ETHYL-7-(2-METHYL-6-(1H-1,2,4-TRIAZOL-3-YL) PYRIDIN-3-YL)-3,4-DIHYDROPYRAZINO(2,3-b)PYRAZIN-2(1H)-ONE, AND A COFORMER, COMPOSITIONS AND METHODS OF USE THEREOF
NZ714742A (en) 2014-04-16 2017-04-28 Signal Pharm Llc Solid forms of 1-ethyl-7-(2-methyl-6-(1h-1,2,4-triazol-3-yl)pyridin-3-yl)-3,4-dihydropyrazino[2,3-b]pyrazin-2(1h)-one, compositions thereof and methods of their use
EP3143021B1 (en) * 2014-05-14 2019-06-12 Pfizer Inc Pyrazolopyridines and pyrazolopyrimidines
WO2017087818A1 (en) * 2015-11-19 2017-05-26 The Regents Of The University Of Michigan Dual src/p38 kinase inhibitor compounds and their use as therapeutic agents
CA3063976A1 (en) 2017-05-23 2018-11-29 Mei Pharma, Inc. Combination therapy
IL271491B2 (en) 2017-06-22 2023-09-01 Celgene Corp Treatment of carcinoma of the liver characterized by hepatitis b virus infection
CN110950868B (zh) * 2018-09-27 2022-05-13 苏州锐明新药研发有限公司 吡唑并嘧啶化合物及制备方法与制备抗癌症药物的应用
CN113549080B (zh) * 2021-08-27 2023-05-16 中国医学科学院放射医学研究所 一类1,2,3-三氮唑并嘧啶类化合物、其制备方法和用途
KR20240015978A (ko) 2022-07-28 2024-02-06 박수산 다층 수력 발전시스템

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN100345830C (zh) * 2000-04-27 2007-10-31 安斯泰来制药有限公司 稠合杂芳基衍生物

Also Published As

Publication number Publication date
SV2010003621A (es) 2011-07-05
NI201000119A (es) 2011-05-04
DOP2010000217A (es) 2010-07-31
ZA201004603B (en) 2011-03-30
KR20100113567A (ko) 2010-10-21
EP2252296A1 (en) 2010-11-24
WO2009091788A1 (en) 2009-07-23
US20090181963A1 (en) 2009-07-16
CN102014914A (zh) 2011-04-13
JP2011510010A (ja) 2011-03-31
CA2712267A1 (en) 2009-07-23
AU2009205501A1 (en) 2009-07-23
ECSP10010346A (es) 2010-08-31
CR11568A (es) 2010-08-11
MA32341B1 (fr) 2011-06-01
MX2010007746A (es) 2010-08-18
AP2010005346A0 (en) 2010-08-31
EA201001017A1 (ru) 2011-02-28
IL206820A0 (en) 2010-12-30
CO6321259A2 (es) 2011-09-20
ZA201005793B (en) 2011-04-28

Similar Documents

Publication Publication Date Title
BRPI0906519A2 (pt) Compostos de 3h--[1,2,3]triazolo[4,5-d]pirimidina, seu uso como mtor cinase e inibidores de pi3 cinase, e sua síntese
BRPI0817681A2 (pt) Compostos de tienopirimidina e pirazolopirimidina e seu uso como inibidores de mtor quinase e pi3 quinase
LTPA2020504I1 (lt) Pakeistieji pirazolo[1,5-a]pirimidino junginiai kaip Trk kinazės slopikliai
BRPI0813831A2 (pt) Compostos de heteroarila bicíclica e seu uso como inibidores de quinase
AU2008228964A8 (en) Pyrazolopyrimidine Analogs and their use as mTOR kinase and PI3 kinase inhibitors
PL2004654T3 (pl) Pochodne pirazolopirymidyny do stosowania jako antagonisty kinazy
BRPI0716749A2 (pt) Compostos pirido (2,3-d) pirimidinona e seu uso como inibidores pi3
CU23886B1 (es) Derivados de pirrolo [2,3-d] pirimidina como inhibidores de proteínas quinasas b
DK2384326T3 (da) Pyrrolo[2,3-d]pyrimidinforbindelser
DK1973910T3 (da) Pyrrolo[3,2-c]pyridin-4-on-2-indolinon-proteinkinaseinhibitorer
PT3184526T (pt) Derivados de pirrolo[2,3-d]pirimidina como inibidores da cinase janus
BRPI0919810A2 (pt) compostos heterocíclicos contendo nitrogênio, sua preparação e seu uso como medicamentos antibacterianos
NO20084526L (no) Tienpyrimidiner med MNKL/MNK2 inhiberende aktivitet for farmasøytiske sammensetninger
BR112013017672A2 (pt) composto de imidazo[4,5-c]quinolin-2-ona e seu uso como inibidor duplo de quinase pi3/mtor
PL2217578T3 (pl) Związki [1,2,4]triazolo[1,5-a]pirydyny i [1,2,4]triazolo[1,5-c]pirymidyny i ich zastosowanie
BRPI0908433A2 (pt) pirrolo[2,3-d]piridinas e empregos destas como inibidores tirosina cinase
BRPI0815043A2 (pt) mcp-1 mutantes antagonistas de glicosaminoglicanos e métodos para o seu uso
ZA200909224B (en) Morpholino pyrimidine derivatives used in diseases linked to mtor kinase and/or pi3k
IL191889A0 (en) Bicyclic compounds with kinase inhibitory activity
BRPI1008850A2 (pt) [1,2,4]triazolo[1,5-a]piridinas como inibidores de quinase
BRPI0907931A2 (pt) Derivado de pirrolopirimidina como inibidor de pi3k e uso do mesmo
DK2406263T3 (da) Pyrazolo[1,5-a]-1,3,5-triazinderivater, deres fremstilling samt deres terapeutiske anvendelse
BRPI0919807A2 (pt) compostos nitrogenosos heterocíclicos , sua preparação e seu uso como medicamentos antibacterianos
SI2004654T1 (sl) Pirazolopirimidinski derivati za uporabo kot kinazni antagonisti
BRPI0822239A2 (pt) Composto de pirazolo[1,5-a] pirimidina

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE AS 4A, 5A E 6A ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2329 DE 25-08-2015 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.